Key Highlights

● CAVA Group (CAVA) closed down 8.93% at $49.99, extending a multi-week slide tied to valuation compression, not new negative news.

● Arrowhead Pharmaceuticals (ARWR) closed down 12.40% at $70.67, a pullback that looks like profit-taking after a record run rather than a setback.

● Cirrus Logic (CRUS) closed up 5.05% at $122.21, bucking the day's weakness on Apple iPhone-cycle optimism.

● All three moves came without a confirmed same-day company-specific catalyst, pointing instead to broader sentiment and positioning shifts.

Three S&P MidCap 400 constituents posted outsized moves in mid-September 2026 trading, underscoring how differently individual stories can play out within the same index. CAVA Group (NYSE:CAVA) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) both dropped sharply, while Cirrus Logic (NASDAQ:CRUS) bucked the day's weakness with a solid gain.

CAVA Group (NYSE:CAVA)

CAVA shares closed down about 8.93% at a reference level near $50 on 15 September 2026, extending a decline of more than 20% over the prior 30 days. No new SEC filing, guidance revision or operating update was identified around the move; the slide instead looks tied to valuation compression, with a trailing price-to-earnings ratio near 89 leaving little room for disappointment as consumer sentiment cools. CAVA's second-quarter fiscal 2026 Revenue rose 31.3% year over year to $365.4 million, so the fundamentals have stayed strong even as the multiple has come in.

Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Arrowhead closed down about 12.40% at a reference level near $71 on 15 September 2026, a double-digit pullback that followed a powerful run to record highs rather than any fresh setback. The company's lead RNAi candidate, plozasiran, recently posted positive Phase 3 results, including a 78% reduction in acute pancreatitis events versus placebo, and its commercial form, REDEMPLO, has been launched with prescription volumes roughly doubling in the fiscal third quarter. With no confirmed new negative trial result or regulatory setback identified, the decline looks more consistent with profit-taking after a record run.

Cirrus Logic (NASDAQ:CRUS)

Cirrus Logic bucked the day's weakness, closing up about 5.05% at $122.21. The gain looks tied to optimism around Apple's iPhone cycle and broader semiconductor sentiment rather than any standalone company catalyst. Cirrus's expanded relationship with Apple, including a Face ID power-IC design win alongside GlobalFoundries, has kept content-growth expectations elevated. Fiscal first-quarter 2027 revenue reached a record roughly $460 million.

One Sector, Three Unrelated Outcomes

For CAVA, the next quarterly print, including same-store sales, traffic and whether full-year guidance holds, will be the key test of whether the slide was sentiment-driven or the start of something more durable. For Arrowhead, attention turns to plozasiran's regulatory timelines and REDEMPLO's commercial uptake, along with whether the pullback gets bought or extends into a broader biotech de-rating. For Cirrus Logic, Apple iPhone build and Demand data, and the timing of the Face ID power-IC ramp, remain the central signposts ahead of its fiscal second-quarter 2027 results.